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background
 
Trachoma, caused by repeated ocular infection with 
 
Chlamydia trachomatis,
 
 is an impor-
tant cause of blindness. Current recommended dosing intervals for mass azithromycin
treatment for trachoma are based on a mathematical model.
 
methods
 
We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of
 
C. trachomatis
 
 before and 2, 6, 12, 18, and 24 months after mass treatment with azithro-
mycin in a Tanzanian community in which trachoma was endemic. For ethical reasons,
at 6, 12, and 18 months, we gave tetracycline eye ointment to residents who had clini-
cally active trachoma.
 
results
 
At baseline, 956 of 978 residents (97.8 percent) received either one oral dose of azith-
romycin or (if azithromycin was contraindicated) a course of tetracycline eye ointment.
The prevalence of infection fell from 9.5 percent before mass treatment to 2.1 percent
at 2 months and 0.1 percent at 24 months. The quantitative burden of ocular 
 
C. tracho-
matis
 
 infection in the community was 13.9 percent of the pretreatment level at 2 months
and 0.8 percent at 24 months. At each time point after baseline, over 90 percent of the
total community burden of 
 
C. trachomatis
 
 infection was found among subjects who had
been positive the previous time they were tested.
 
conclusions
 
The prevalence and intensity of infection fell dramatically and remained low for two
years after treatment. One round of very-high-coverage mass treatment with azithro-
mycin, perhaps aided by subsequent periodic use of tetracycline eye ointment for per-
sons with active disease, can interrupt the transmission of ocular 
 
C. trachomatis
 
 infection.
abstract
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rachoma is a chronic keratocon-
 
junctivitis caused by the bacterium 
 
Chla-
mydia trachomatis
 
. Resolution of ocular
chlamydial infections may be accompanied by
scarring of the conjunctivae. Over many years, con-
traction of upper-lid scars produced during multi-
ple episodes of infection
 
1
 
 causes the eyelashes of
some patients to deviate inward so that they abrade
the globe. This complication, termed “trichiasis,”
leads to scarring of the cornea. Trachoma is the
most common infectious cause of blindness.
 
2
 
Until the 1990s, attempts to control trachoma
with antibiotics yielded mostly disappointing re-
sults. Mass administration of oral sulfonamides in
North America in the 1930s and 1940s was associ-
ated with an unacceptably high incidence of severe
adverse reactions, including the Stevens–Johnson
syndrome.
 
3,4
 
 Mass distribution of tetracycline eye
ointment (subsequently referred to as tetracycline)
in a number of countries in the 1950s and 1960s
 
5
 
was also ultimately unsuccessful. Because tetracy-
cline is unpleasant to apply and requires many
weeks’ use to be effective, compliance is poor. The
discovery that single-dose azithromycin is at least as
effective as a prolonged course of tetracycline
 
6-10
 
was therefore a major advance.
Using a mathematical model to estimate the fre-
quency of mass treatment with azithromycin that is
required to eliminate trachoma, Lietman et al. sug-
gested twice-yearly treatment in communities in
which more than 50 percent of children have clini-
cally active trachoma and annual treatment in com-
munities in which less than 35 percent of children
have active trachoma.
 
11
 
 The model, however, as-
sumed a treatment efficacy of 95 percent, a homo-
geneous distribution of cases, and the absence of
immigration. The model was also based on analy-
ses of disease, although there is poor correlation
between disease and 
 
C. trachomatis
 
 infection.
 
12-14
 
The usual current practice, however, is to offer an-
nual treatment wherever the prevalence of active
trachoma among children is 20 percent or greater.
Empirical data on the rates of reinfection after mass
treatment with azithromycin are required. We used
a quantitative polymerase-chain-reaction (PCR) as-
say to examine the effect of high-coverage mass
distribution of azithromycin on ocular chlamydial
infection in a community in Tanzania in which tra-
choma was endemic.
The study was approved by the ethics committees
of the Kilimanjaro Christian Medical Centre, Moshi,
Tanzania, and the London School of Hygiene and
Tropical Medicine, London. Written informed con-
sent was obtained from all subjects or their parents.
 
population, enrollment, baseline 
examination, and treatment
 
We conducted the study in Kahe Mpya subvillage,
Rombo District, Tanzania. This community has
been described previously.
 
15
 
 In July 2000, we exam-
ined each consenting resident for trachoma, using
the simplified system of the World Health Organi-
zation.
 
16
 
 This grading system includes five signs:
trachomatous inflammation–follicular, defined as
five or more follicles at least 0.5 mm in diameter
in the central plate; trachomatous inflammation–
intense, defined as pronounced inflammatory thick-
ening of the upper tarsal conjunctiva obscuring at
least half the normal deep tarsal vessels; trachoma-
tous scarring; trachomatous trichiasis; and corneal
opacity. We then swabbed the tarsal conjunctiva of
each subject’s right eye, using a highly standard-
ized swabbing technique.
 
15
 
 Every nonpregnant res-
ident 12 months of age or older was then offered
one directly observed oral dose of 20 mg of azithro-
mycin per kilogram of body weight (maximum, 1 g).
Children younger than 12 months of age and preg-
nant women were not given azithromycin, but in-
stead were offered two tubes of 1 percent tetracy-
cline, with instructions to apply the ointment twice
daily for 6 weeks. Azithromycin was donated by
Pfizer through the International Trachoma Initia-
tive, Dar es Salaam, Tanzania. Neither of these or-
ganizations had any role in the study design, data
analysis, manuscript preparation, or the publication
decision. Tetracycline was obtained on the open
market. All treatment was provided free to subjects.
 
follow-up
 
We conducted a census review monthly for 24
months after treatment. At each review, we checked
the residence status of each registered subject and
offered enrollment to new residents (persons who
had arrived and infants who had been born in the
previous month). Conjunctival swabs were obtained
from the new residents at the time of enrollment.
For all subjects, follow-up examination and swab-
t methods
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bing were performed by the same examiner at 2, 6,
12, 18, and 24 months. Subjects who moved out of
the subvillage were not seen at follow-up. Our co-
hort therefore consisted of residents seen at inter-
vals through 24 months of follow-up (an open, or
dynamic, population),
 
17
 
 rather than the people who
were residents at baseline. Because continuous in-
flammation predicts the development of conjuncti-
val scarring,
 
18
 
 for ethical reasons, at 6, 12, and 18
months, we gave two tubes of tetracycline to sub-
jects with active disease (as defined by the presence
of trachomatous inflammation–follicular, tracho-
matous inflammation–intense, or both in either
eye
 
16
 
).
We took stringent precautions to prevent carry-
over contamination between subjects.
 
15
 
 Swabs were
stored dry on ice (4°C) in the field, frozen at ¡20°C
within eight hours after collection, and then flown
on ice to London. PCR methods have been presented
in detail elsewhere.
 
15
 
 Briefly, we undertook primary
screening for the presence or absence of 
 
C. tracho-
matis
 
 DNA, using a highly sensitive qualitative PCR
assay (Amplicor, Roche Molecular Systems).
 
19,20
 
For positive and equivocal samples, we extracted
DNA from the Amplicor preparation using the
QIAamp kit (Qiagen) and amplified it in the Light-
Cycler (Roche) using primers specific for a 123-bp
sequence within constant domain 3 of the single-
copy chromosomal gene 
 
omp1
 
. For all but 20 Am-
plicor-positive samples (15 samples obtained at
baseline and 5 obtained at two months), quantifi-
cation was performed twice, on two independent
4-µl aliquots, amplified on separate runs; we de-
rived the final number of copies by calculating the
geometric mean of the two estimates.
 
statistical analysis
 
We double-entered data in Microsoft Access soft-
ware (version 97 SR-2); discrepancies were checked
against the original forms. We performed statistical
analyses using Stata 7 software. To compare pro-
portions of subjects with infection and subjects with
disease at different time points, allowing for the par-
tial matching of data, we used logistic generalized
estimating equations.
 
21
 
 The exception was the com-
parison of infection at 24 months (when only one
subject was positive) with infection at other time
points. For this analysis, we included only matched
records and used the exact binomial version of
McNemar’s test.
 
22
 
 Our summary statistic for the
quantitative burden of ocular 
 
C. trachomatis
 
 infection
in the community was an adjusted geometric mean
derived by adding 1 copy of 
 
omp1
 
 per milliliter (0.55
copy per swab) to each subject’s conjunctival load,
taking the geometric mean, then subtracting the
same value (1 copy of 
 
omp1
 
 per milliliter). We calcu-
lated confidence intervals for this index by means of
bootstrap analysis, with 10,000 replicates.
 
enrollment, treatment, and follow-up
 
At baseline, as previously reported,
 
15
 
 we examined
and obtained a conjunctival swab from 956 of the
978 residents of Kahe Mpya (97.8 percent). Of the
956 subjects, 916 (95.8 percent of subjects and 93.7
results
 
* The community ocular 
 
C. trachomatis
 
 load is the adjusted geometric mean of the number of copies of 
 
omp1,
 
 determined 
by quantitative PCR, in the swab obtained from each subject at each time point. CI denotes confidence interval.
 
† P<0.001 for the comparison with the baseline value.
 
Table 1. Subjects with Swabs Positive for 
 
Chlamydia trachomatis
 
 and the Community Ocular 
 
C. trachomatis
 
 Load.
Time
Total No. of
Residents Subjects Tested
Subjects with
Positive Swabs Community Ocular 
 
C. trachomatis 
 
Load
 
*
Adjusted Geometric Mean
(95% CI) % of Baseline
 
number (percent)
 
Baseline 978 956 (97.8) 91 (9.5) 0.423 (0.312–0.564) 100.0
2 Months 959 905 (94.4) 19 (2.1) 0.059 (0.032–0.094) 13.9†
6 Months 973 879 (90.3) 13 (1.5) 0.037 (0.018–0.064) 8.7†
12 Months 984 907 (92.2) 8 (0.9) 0.020 (0.008–0.037) 4.7†
18 Months 978 889 (90.9) 5 (0.6) 0.015 (0.003–0.036) 3.6†
24 Months 985 842 (85.5) 1 (0.1) 0.003 (0–0.020) 0.8†
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percent of residents) were then given azithromycin,
and 39 (4.1 percent of subjects and 4.0 percent of
residents) were given tetracycline. In total, 955 (97.6
percent of residents) were given antibiotics; 1 60-
year-old woman underwent swabbing but declined
treatment.
Over a follow-up period of 24 months, 195 new
residents (113 immigrants and 82 newborns) were
registered. The number of new residents, howev-
er, was approximately balanced by the number of
deaths and emigrations. The crude emigration rate
was 0.23 per person-year; emigrants returned at a
 
Figure 1. Number of Copies of 
 
omp1
 
 per Swab According to Age and Sex at Baseline (Panel A), 2 Months (Panel B), 
6 Months (Panel C), 12 Months (Panel D), 18 Months (Panel E), and 24 Months (Panel F).
 
Swabs that were negative on a highly sensitive PCR assay are not shown.
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rate of 0.62 per person-year. The rate of participa-
tion at follow-up was high (Table 1).
 
changes in the prevalence of infection
 
The prevalence of 
 
C. trachomatis
 
 conjunctival infec-
tion decreased progressively over time (Table 1).
The decrease from baseline to two months was sig-
nificant (P<0.001). At 6, 12, 18, and 24 months,
the prevalence of infection remained significantly
lower than it had been before treatment (P<0.001
for each comparison), and in each instance it was
below, but not significantly below, that recorded
for the previous round.
 
changes in the intensity of infection
 
In general, at each time point, the highest chla-
mydial loads were found in the youngest age groups
(Fig. 1). No subject 16 years of age or older had an
ocular chlamydial infection at 6, 12, or 24 months,
though two women (age, 62 and 88 years) were in-
fected at 18 months.
The community burden of ocular 
 
C. trachomatis
 
infection dropped to 13.9 percent of the pretreat-
ment level 2 months after mass treatment and there-
after continued to decrease; the burden was 8.7 per-
cent of the baseline level at 6 months, 4.7 percent at
12 months, 3.6 percent at 18 months, and 0.8 per-
cent at 24 months (Table 1 and Fig. 2A). Decreases
in this index were observed in all age and sex groups
(Fig. 2B).
 
changes in the prevalence of active 
disease
 
At baseline, 195 of 956 subjects (20.4 percent) had
active disease (trachomatous inflammation–follicu-
lar, trachomatous inflammation–intense, or both in
either eye
 
16
 
). The overall prevalence of active tracho-
ma was significantly lower at each follow-up point
than it had been at baseline (P<0.001 for each com-
parison). The overall prevalence at 12 months (94
cases of active disease among 907 subjects, or 10.4
percent) was significantly higher than it was at ei-
ther 6 months (54 cases among 879 subjects, or 6.1
percent) or 18 months (54 among 889, or 6.1 per-
cent; P<0.001 for each comparison). The peak prev-
alence of active disease occurred between the ages
of one and four years at each time point (Fig. 3).
 
intensity of infection in subgroups 
of the population
 
At baseline, 98.1 percent of the community burden
of ocular chlamydial infection was accounted for
by 174 subjects with clinically active disease in the
swabbed eye. Subjects with clinically active disease
accounted for proportionately less of the total chla-
mydial burden at 2, 6, and 12 months, but at 18 and
24 months, when there were very few infections,
this subgroup accounted for 100 percent of the to-
tal (Table 2). At all time points, the community bur-
den of infection was disproportionately borne by
children under the age of 10 years (Table 2).
 
effect of antibiotics on the transmission 
of infection
 
There were few new infections after mass treat-
ment (Table 2). At each time point after baseline,
over 90 percent of the total burden of 
 
C. trachomatis
 
was found among subjects who had been positive
the previous time they were tested. Of 195 subjects
 
Figure 2. Overall (Panel A) and Age-Specific (Panel B) Community Ocular 
 
Chlamydia trachomatis
 
 Load at Each Time Point.
 
Vertical bars in Panel A are 95 percent confidence intervals.
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who were enrolled after baseline, none of the new-
borns and only two of the immigrants were posi-
tive at enrollment: one was a 16-year-old girl who
arrived just before the 2-month census review (test
result, 15 copies of 
 
omp1
 
 per swab at 2 months),
and the other was a 13-year-old girl who arrived
just after the 5-month census review (test result, 19
copies of 
 
omp1
 
 per swab at 6 months and 162 cop-
ies per swab at 12 months). Neither had any sign of
active disease; neither received tetracycline. House-
hold contacts of these subjects were negative for
 
C. trachomatis
 
 at the follow-up evaluations after their
arrival, suggesting that the girls were not sources
of secondary infection. At 12 months, the test re-
sult of 162 copies of 
 
omp1 
 
per swab for the 13-year-
old represented a large proportion of the total
burden of infection (Table 2), given that the total
number of copies of 
 
omp1
 
 in the community was
503 at that time, as compared with 1,578,724 at
baseline.
At six months, 54 subjects were given tetracy-
cline, including 7 subjects who were positive for
 
C. trachomatis
 
 and who accounted for nearly half the
total community burden of infection at that time
(Table 2). At the next follow-up evaluation (12
months), these 54 subjects still accounted for 15.0
percent of the total community burden. At 12
months, 94 subjects were given tetracycline, includ-
ing 5 whose ocular infection represented 61.9 per-
cent of the total community burden; at the next
follow-up, the ocular infection in this subgroup
represented 99.8 percent of the total community
burden. At 18 months, 54 subjects were given tet-
racycline, including 3 whose ocular infection rep-
resented 99.8 percent of the total community bur-
den; 1 of those 3 was still infected (and was the only
infected subject) at 24 months.
In this Tanzanian community in which trachoma
was endemic, the prevalence of ocular 
 
C. trachomatis
 
infection fell dramatically after mass treatment
with azithromycin. The decline in the prevalence of
infection continued for two years, at which time
there was only 1 infected subject among 842 who
were tested. This observation contrasts starkly with
the predicted pattern of rapid community reinfec-
tion used in a model of the effect of mass treat-
ment.
 
11
 
 Subjects who were positive on PCR testing
after treatment had relatively low-intensity infec-
tions, as demonstrated by the community ocular
 
C. trachomatis
 
 load, which was 0.423 at baseline,
0.059 (13.9 percent of the baseline value) two
months after treatment, and 0.003 (0.8 percent of
the baseline value) at two years. These large, pro-
discussion
 
Figure 3. Prevalence of Active Disease over Time among the Various Age Groups.
 
Active disease was defined according to the World Health Organization simplified grading system, by the presence 
of trachomatous inflammation–follicular, trachomatous inflammation–intense, or both in either eye.
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gressive decreases in the prevalence and intensity
of infection suggest that transmission was stopped.
This hypothesis is supported by analyses of the dis-
tribution of infection: at each evaluation after treat-
ment, over 90 percent of the ocular chlamydial bur-
den was found among subjects who had had a
positive result the previous time they were tested,
and less than 10 percent among those who had ei-
ther not been tested before or whose previous test
had been negative. There are no known animal or
environmental reservoirs of human 
 
C. trachomatis
 
strains.
 
23,24
 
The most likely explanation for the interruption
in the transmission of infection is the extremely
high antibiotic coverage achieved with mass treat-
ment. Because the study was not designed to test the
efficacy of antibiotic treatment, there was no place-
bo group, and alternative explanations for our find-
ings should be considered. First, neither enhanced
personal hygiene among study participants nor a
reduction in the density of eye-seeking flies in the
village, each of which may reduce the transmission
of 
 
C. trachomatis,
 
25
 
 can be ruled out. However, stud-
ies demonstrating the effectiveness of these mea-
sures involved highly intensive interventions
 
26,27
 
;
no such interventions were undertaken in the village
during our study. Second, we cannot rule out a small
contribution from a regional secular trend.
 
28
 
 Third,
 
Table 2. Distribution of the Total Community Ocular 
 
Chlamydia trachomatis
 
 Load among Various Subgroups 
of the Population at Each Time Point.*
Variable
Baseline
(N=956)
2 Months
(N=905)
6 Months
(N=879)
12 Months
(N=907)
18 Months
(N=889)
24 Months
(N=842)
Clinical signs of trachoma†
 
TF, TI, or both
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
98.1
58/174
70.7
9/49
40.0
6/42
62.0
5/77
99.8 
3/43
100 
1/49
TI with or without TF
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
92.4
41/111
33.9
5/24
28.6
3/25
0
0/30
99.0
2/22
100 
1/14
TI but not TF
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
65.6
11/56
0.7
1/9
0
0/14
0
0/18
0
0/11
0
0/10
TF with or without TI
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
32.5
47/118
70.0
8/40
40.0
6/28
62.0
5/59
99.8 
3/32
100 
1/39
Both TF and TI
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
26.9
30/55
33.3
4/15
28.6
3/11
0
0/12
99.0
2/11
100 
1/4
TF but not TI
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
5.7
17/63
36.8
4/25
11.4
3/17
62.0
5/47
0.8
1/21
0
0/35
Neither TF nor TI
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
1.9
33/782
29.3
10/855
60.0
7/837
38.2
3/830
0.2
2/846
0
0/793
 
Sex and age group
 
Females <10 yr
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
82.7
33/174
56.5
7/177
84.0
5/164
7.6
2/177
0.8
1/172
0
0/164
Males <10 yr
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
14.4
24/186
36.9
7/174
14.8
5/167
58.3
4/177
98.9
2/176
100 
1/168
Females ≥10 yr
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
0.5
16/360
6.5
5/338
1.2
3/329
34.2‡
2/340
0.2
2/329
0
0/317
Males ≥10 yr
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
2.3
18/236
0
0/216
0
0/219
0
0/213
0
0/212
0
0/193
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a proportion of the observed longevity of the reduc-
tion in the chlamydial burden could be ascribed to
tetracycline treatment in residents with active cases
at 6, 12, and 18 months. In each instance, the prev-
alence of infection in those given tetracycline was
lower six months after treatment than at the time
the ointment was dispensed. However, 15 to 100
percent of the (diminishing) total community bur-
den at each of the final three time points was found
among subjects who had received tetracycline at
the previous evaluation. In general, the evidence
supporting the efficacy of tetracycline is weak.
 
29
 
Many people who receive a prescription for a six-
week course probably fail to complete it.
 
25,30
 
 In the
present study, as in control programs, compliance
with tetracycline treatment was not monitored.
Children less than 10 years old accounted for at
least 90 percent of the total burden of ocular chla-
mydial infection at each time point except the 12-
month follow-up (Table 2), when one 13-year-old
immigrant accounted for a large fraction of the to-
tal community burden. In contrast, the contribution
of subjects with active disease to the total commu-
nity reservoir of ocular chlamydiae was less consis-
tent over time. From a programmatic viewpoint, this
distinction is important: accurate clinical grading
requires training and experience, and skilled oph-
thalmic personnel are scarce in Africa.
 
31
 
 Determin-
ing children’s ages is more straightforward. In Kahe
Mpya at baseline, successful treatment exclusively
of the 360 children under the age of 10 years (37.7
percent of the subvillage’s 956 residents) would
 
* The percentage of total copies is the percentage of the total contributed by each subgroup. TF denotes trachomatous in-
flammation–follicular, TI trachomatous inflammation–intense, and NA not applicable.
†
 
C. trachomatis
 
 burden in groups with different clinical signs in the swabbed eye is given. Active disease was defined ac-
cording to the World Health Organization simplified grading system. The sum of the percentages for the various sub-
groups at each time point exceeds 100 percent because the clinical categories used are not mutually exclusive. Exami-
nation data were missing for one (
 
C. trachomatis
 
–negative) subject at two months.
‡ The principal contribution to the relatively high percentage of the total burden among female subjects 10 years of age 
or older at 12 months was from a 13-year-old girl whose positive result represented 32 percent of the community burden 
of 
 
C. trachomatis
 
 infection at that time point. She had arrived between five and six months after baseline and therefore 
had not received azithromycin.
§ Subjects who arrived after baseline included those who were born after baseline and those who immigrated to the subvil-
lage after baseline and who therefore had not been present at the time of mass treatment.
¶ No tetracycline was distributed at two months.
¿ Subjects who were not previously positive were those who had not been positive the previous time they were tested
or who had not previously been tested.
 
**Previously positive subjects were those who had been positive the previous time they were tested.
 
Table 2. (Continued.)
Variable
Baseline
(N=956)
2 Months
(N=905)
6 Months
(N=879)
12 Months
(N=907)
18 Months
(N=889)
24 Months
(N=842)
Time of enrollment or positivity 
 
Enrollment after baseline§
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
NA
NA
0.1 
1/29 
0.5 
1/74
32.3 
1/126
0  
0/162
0 
0/195
Receipt of tetracycline at this time point
Percentage of total copies of 
 
omp1
 
No. positive/total no. of subjects
NA
NA
NA¶
NA
44.7 
7/54
61.9 
5/94
99.8 
3/54
NA
NA
Previous treatment with tetracycline
Percentage of total copies of 
 
omp1
No. positive/total no. of subjects
NA
NA
NA
NA
NA
NA
15.0
4/54
99.8 
3/94
100 
1/54
Subjects not previously positive¿
Percentage of total copies of omp1
No. positive/total no. of subjects
NA
NA
6.7 
7/817
0.9 
4/863
7.6 
2/894
0.2 
2/882
0 
0/836
Previously positive subjects**
Percentage of total copies of omp1
No. positive/total no. of subjects
NA
NA
93.3 
12/88
99.1 
9/16
92.4 
6/13
99.8 
3/7
100 
1/6
All subjects
Percentage of total copies of omp1
No. positive/total no. of subjects
100 
91/956
100  
19/905
100  
13/879
100
8/907
100  
5/889
100 
1/842
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
n engl j med 351;19 www.nejm.org november 4, 2004
The new england journal of medicine
1970
have eliminated 97.2 percent of the community’s
chlamydial burden (Table 2). Further work is needed
to determine whether this approach could be an ef-
fective and acceptable alternative to mass treatment.
The prevalence of clinically active disease was
significantly higher at 12 months than at either 6 or
18 months, whereas both the prevalence and the
intensity of ocular C. trachomatis infection showed a
consistent downward trend over these three time
points. Seasonal fluctuations in nonchlamydial oc-
ular pathogens might be responsible for this trend:
it has been hypothesized that a variety of microor-
ganisms induce conjunctival changes that are rem-
iniscent of active trachoma in persons who have
previously had ocular chlamydial infections.14
Our results are extremely encouraging. They
have three major implications. First, it seems likely
that the observed magnitude and duration of the
quantitative reduction in infection were principally
due to high baseline treatment coverage, which ap-
proached the 100 percent coverage assumed in the
model devised by Lietman et al.11 Routine, com-
munity-based distribution of antibiotics for tra-
choma control in Tanzania results in a much lower
rate of coverage, averaging 80 to 90 percent. Oper-
ational research is needed to explore the reasons
for the incomplete acceptance of offered antibiotic
therapy. Screening and distribution of tetracycline
to those with active disease after mass treatment
may also have contributed to our dramatic results.
If screening and tetracycline treatment are shown
to be important, this approach should not be dis-
missed as a possible adjuvant to baseline mass
treatment, especially if such a strategy is critical for
local elimination of trachoma.
Second, if near-complete coverage can be ob-
tained, treatment with azithromycin less frequent-
ly than every 12 months may be effective. Trials
comparing the effect of current practice with that
of extended treatment intervals should be a priori-
ty. The predicted need for reduced dosing intervals
in areas with a very high prevalence of disease11
also requires investigation.
Third, signs of active trachoma have again13
proved unhelpful as indicators of the effect of treat-
ment. The prevalence of trachomatous inflamma-
tion–follicular among children one to nine years of
age was 36.0 percent at baseline, 13.2 percent at
two months, and 16.3 percent at two years, yet the
community load of ocular C. trachomatis infection
fell by more than 99 percent during this interval.
Possible reasons for the discrepancy between the
prevalence of infection and the prevalence of dis-
ease have been discussed previously.32 An accu-
rate, inexpensive, and rapid C. trachomatis assay that
can be used in the field to estimate the prevalence of
ocular infection in a given community is required
for areas in which antibiotics have been distributed
or in which the prevalence of active disease is low at
the first assessment.12,14 Such a test would help pro-
gram managers to direct antibiotics to the commu-
nities that need them most and to measure progress
toward the elimination of trachoma.
We are indebted to the village chairmen, elders, and villagers of
Kahe Mpya for their good humor and willingness to be involved; to
our field teams for help with collection of data and specimens; to Dr.
Shanshan Li and Ewen Cameron for excellent laboratory assistance;
and to the members of our research steering committee. This study
was supported by grants from the Wellcome Trust/Burroughs
Wellcome Fund (059134), the Edna McConnell Clark Foundation
(99100), the International Trachoma Initiative (01-032), and the
Medical Research Council (9826361).
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